Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 621 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... March 21, 2022 EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 First Prospective Description of Familial EGFR-mutated Lung Cancer August 23, 2023 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 Load more HOT NEWS Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching... Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... Lung Adenocarcinoma with Mucinous Histology OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and...
